Analysis of genetic and non genetic risk factors for cisplatin ototoxicity in pediatric patients
Authors:
- Yüksel OlgunYOYüksel Olgun
- Zekiye AltunZAZekiye Altun
- Dilek İnceDIDilek İnce
- Kamer MutafoğluKMKamer Mutafoğlu
- 1 November 2016
- journal article
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 90, 64-69
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Cisplatin-induced Ototoxicity in Pediatric Solid TumorsJournal of Pediatric Hematology/Oncology, 2013
- Platinum Compounds: A Hope for Future Cancer ChemotherapyAnti-Cancer Agents in Medicinal Chemistry, 2013
- Risk factors for cisplatin‐associated ototoxicity in pediatric oncology patientsPediatric Blood & Cancer, 2012
- Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapyNature Genetics, 2009
- Cisplatin Ototoxicity and Protection: Clinical and Experimental StudiesThe Tohoku Journal of Experimental Medicine, 2009
- Mechanisms of cisplatin ototoxicity and progress in otoprotectionCurrent Opinion in Otolaryngology & Head and Neck Surgery, 2007
- Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatinThe Pharmacogenomics Journal, 2007
- Mechanisms of cisplatin-induced ototoxicity and preventionHearing Research, 2007
- Predicting cisplatin ototoxicity in children: the influence of age and the cumulative doseEuropean Journal of Cancer, 2004
- Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatinAnti-Cancer Drugs, 2000